da Silva PEA - Search Results

1

Alternative Pharmaceutical Formulation for Oral Administration of Rifampicin.

Halicki PCB, Hädrich G, Boschero R, Ferreira LA, von Groll A, da Silva PEA, Dora CL, Ramos DF. Halicki PCB, et al. Among authors: da silva pea. Assay Drug Dev Technol. 2018 Dec;16(8):456-461. doi: 10.1089/adt.2018.874. Epub 2018 Oct 16. Assay Drug Dev Technol. 2018. PMID: 30325673

2

Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin.

Corrêa Barros LP, Del Rio KP, Carvalho TDSC, Pinto MDCFR, de Moura KCG, Halicki PCB, Ramos DF, da Silva PEA. Corrêa Barros LP, et al. Among authors: da silva pea. Tuberculosis (Edinb). 2018 Jul;111:198-201. doi: 10.1016/j.tube.2018.06.015. Epub 2018 Jul 3. Tuberculosis (Edinb). 2018. PMID: 30029908

3

Tuberculosis Treatment Facilitated by Lipid Nanocarriers: Can Inhalation Improve the Regimen?

Hädrich G, Boschero RA, Appel AS, Falkembach M, Monteiro M, da Silva PEA, Dailey LA, Dora CL. Hädrich G, et al. Among authors: da silva pea. Assay Drug Dev Technol. 2020 Oct;18(7):298-307. doi: 10.1089/adt.2020.998. Assay Drug Dev Technol. 2020. PMID: 33054379 Review.

4

Benzo[a]phenazine derivatives: Promising scaffolds to combat resistant Mycobacterium tuberculosis.

Halicki PCB, da Silva EN Júnior, Jardim GAM, Almeida RG, Vicenti JRM, Gonçalves BL, da Silva PEA, Ramos DF. Halicki PCB, et al. Among authors: da silva pea. Chem Biol Drug Des. 2021 Sep;98(3):352-362. doi: 10.1111/cbdd.13853. Epub 2021 Jun 24. Chem Biol Drug Des. 2021. PMID: 33932096

5

Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis.

da Silva PE, Von Groll A, Martin A, Palomino JC. da Silva PE, et al. FEMS Immunol Med Microbiol. 2011 Oct;63(1):1-9. doi: 10.1111/j.1574-695X.2011.00831.x. Epub 2011 Jul 4. FEMS Immunol Med Microbiol. 2011. PMID: 21668514 Free article. Review.

6

Antibiofilm Potential of Arenecarbaldehyde 2-Pyridinylhydrazone Derivatives Against Acinetobacter baumannii.

Halicki PCB, Radin V, von Groll A, Nora MV, Pinheiro AC, da Silva PEA, Ramos DF. Halicki PCB, et al. Among authors: da silva pea. Microb Drug Resist. 2020 Dec;26(12):1429-1436. doi: 10.1089/mdr.2019.0185. Epub 2019 Nov 26. Microb Drug Resist. 2020. PMID: 31770073

7

Development of Lipid Nanocarriers for Tuberculosis Treatment: Evaluation of Suitable Excipients and Nanocarriers.

Hädrich G, Vaz GR, Boschero R, Appel AS, Ramos C, Halicki PCB, Bidone J, Teixeira HF, Muccillo-Baisch AL, Dal-Bó A, Silva Pinto L, Dailey LA, Da Silva PEA, Ramos DF, Dora CL. Hädrich G, et al. Among authors: da silva pea. Curr Drug Deliv. 2021;18(6):770-778. doi: 10.2174/1567201818666210212092112. Curr Drug Deliv. 2021. PMID: 33583376

8

Improving tuberculosis control through the partnership between university and the health system.

Valença MS, da Rocha JZ, Ramis IB, Carrion LL, Madruga C, de Macedo MB, Scaini CJ, von Groll A, da Silva PE. Valença MS, et al. Rev Soc Bras Med Trop. 2012 Jul-Aug;45(4):491-5. doi: 10.1590/s0037-86822012005000004. Epub 2012 Jul 5. Rev Soc Bras Med Trop. 2012. PMID: 22767097 Free article.

9

Mycobacterium tuberculosis belonging to family LAM and sublineage RD(Rio): common strains in Southern Brazil for over 10 years.

Soares RO, de Macedo MB, von Groll A, da Silva PE. Soares RO, et al. Braz J Microbiol. 2014 Mar 10;44(4):1251-5. doi: 10.1590/s1517-83822013000400032. eCollection 2013 Dec. Braz J Microbiol. 2014. PMID: 24688519 Free PMC article.

10

Molecular typing of Mycobacterium bovis isolates: a review.

Ramos DF, Tavares L, da Silva PE, Dellagostin OA. Ramos DF, et al. Braz J Microbiol. 2014 Aug 29;45(2):365-72. doi: 10.1590/s1517-83822014005000045. eCollection 2014. Braz J Microbiol. 2014. PMID: 25242917 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page